[ALLERGEN IMMUNOTHERAPY IN CHILDREN]

Area of Science:

• Immunology
• Pediatrics
• Allergy

Context:

• Children possess high immune system plasticity, suggesting potential for effective allergen immunotherapy (AIT).
• Current systematic reviews lack robust evidence for superior AIT efficacy in children regarding allergic symptom amelioration.
• Limited studies in pediatric populations contribute to the uncertainty surrounding AIT's clinical benefits for symptom relief.

Purpose:

• To evaluate the efficacy and disease-modifying potential of allergen immunotherapy in children.
• To explore the preventive effects of AIT against asthma development and new-onset sensitization in pediatric allergic rhinitis patients.
• To identify the challenges and needs for developing safer and more effective AIT methods for infants and young children.

Summary:

• While AIT in children may not yet demonstrate superior clinical efficacy for symptom reduction compared to adults, emerging evidence suggests a significant role in preventing asthma inception.
• Allergen immunotherapy shows promise in halting the progression of allergic diseases, often termed the "allergy march," by preventing sensitization to new allergens in children.
• The potential for AIT to stop the "allergy march" in children is a key finding, highlighting its disease-modifying capabilities.

Impact:

• Findings underscore the potential of AIT as a disease-modifying treatment for pediatric allergic diseases, particularly in preventing asthma and the spread of allergies.
• The study highlights the need for earlier AIT initiation, ideally in infancy, to maximize preventive benefits.
• Further research and development are crucial to overcome challenges related to adverse events and administration methods, paving the way for safer and more effective pediatric AIT.